文献速递肝病胃肠动力与功能性疾病

利福昔明-α减少肝硬化伴脑病患者肠道来源炎症与黏蛋白降解:RIFSYS随机对照试验

Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial.
PubMed 文献 · J Hepatol · 2021-09-24

这项安慰剂对照双盲机制研究纳入38例肝硬化伴肝性脑病患者,1:1随机接受利福昔明-α 550mg每日两次或安慰剂90天。利福昔明-α未使30天中性粒细胞氧化爆发较基线下降50%(p=0.48),但30天时HE分级正常化(p=0.014)、PHES改善(p=0.009),并降低中性粒细胞TLR-4表达(p=0.021)和血浆TNF-α(p<0.001),减少感染发生(OR 0.21;95%CI 0.05-0.96)。

要点

  • 利福昔明-α未达主要终点(30天中性粒细胞氧化爆发下降50%)。
  • 利福昔明-α使HE分级正常化并改善PHES,降低感染风险(OR 0.21)。
  • 利福昔明-α抑制口腔化肠道菌群、减少黏蛋白降解并减轻全身炎症。

核心结论

  • 利福昔明-α可缓解显性和隐性肝性脑病,降低感染可能性,减少肠道口腔化并减轻全身炎症。
  • 利福昔明-α可能通过促进肠屏障修复改善肝硬化中的细菌易位和全身内毒素血症。

研究设计与样本

  • 安慰剂对照、双盲、机制性研究,38例肝硬化伴肝性脑病患者按1:1随机接受利福昔明-α 550mg每日两次或安慰剂90天。
  • 主要结局为30天时中性粒细胞氧化爆发较基线下降50%;次要结局包括PHES和神经认知功能、唾液和粪便宏基因组测序、血浆和粪便代谢谱、全血细菌DNA定量、中性粒细胞TLR-2/4/9表达及血浆/粪便细胞因子分析。

主要发现

  • 利福昔明-α组30天时未达到中性粒细胞自发氧化爆发较基线下降50%(p=0.48)。
  • 利福昔明-α组30天时HE分级正常化(p=0.014),PHES改善(p=0.009)。
  • 利福昔明-α组30天时循环中性粒细胞TLR-4表达降低(p=0.021),血浆TNF-α降低(p<0.001)。
  • 利福昔明-α抑制肠道口腔化,降低富含唾液酸酶的黏蛋白降解菌(链球菌属、Veillonella atypica和parvula、Akkermansia和Hungatella)水平。
  • 利福昔明-α组感染发生风险更低(OR 0.21;95%CI 0.05-0.96)。

关键数值与推荐

  • 利福昔明-α剂量为550mg每日两次,疗程90天。
  • 主要结局阈值:30天时中性粒细胞氧化爆发较基线下降50%。
  • 感染风险:利福昔明-α组OR 0.21(95%CI 0.05-0.96)。

临床怎么用

  • 利福昔明-α可用于肝硬化伴肝性脑病患者,以促进HE缓解并降低感染风险。
  • 其机制可能涉及抑制口腔来源的黏蛋白降解菌、减轻全身炎症和修复肠屏障。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Rifaximin-α is efficacious for the prevention of recurrent hepatic encephalopathy (HE), but its mechanism of action remains unclear. We postulated that rifaximin-α reduces gut microbiota-derived endotoxemia and systemic inflammation, a known driver of HE. METHODS: In a placebo-controlled, double-blind, mechanistic study, 38 patients with cirrhosis and HE were randomised 1:1 to receive either rifaximin-α (550 mg BID) or placebo for 90 days. PRIMARY OUTCOME: 50% reduction in neutrophil oxidative burst (OB) at 30 days. SECONDARY OUTCOMES: changes in psychometric hepatic encephalopathy score (PHES) and neurocognitive functioning, shotgun metagenomic sequencing of saliva and faeces, plasma and faecal metabolic profiling, whole blood bacterial DNA quantification, neutrophil toll-like receptor (TLR)-2/4/9 expression and plasma/faecal cytokine analysis. RESULTS: Patients were well-matched: median MELD (11 rifaximin-α vs. 10 placebo). Rifaximin-α did not lead to a 50% reduction in spontaneous neutrophil OB at 30 days compared to baseline (p = 0.48). However, HE grade normalised (p = 0.014) and PHES improved (p = 0.009) after 30 days on rifaximin-α. Rifaximin-α reduced circulating neutrophil TLR-4 expression on day 30 (p = 0.021) and plasma tumour necrosis factor-α (TNF-α) (p <0.001). Rifaximin-α suppressed oralisation of the gut, reducing levels of mucin-degrading sialidase-rich species, Streptococcus spp, Veillonella atypica and parvula, Akkermansia and Hungatella. Rifaximin-α promoted a TNF-α- and interleukin-17E-enriched intestinal microenvironment, augmenting antibacterial responses to invading pathobionts and promoting gut barrier repair. Those on rifaximin-α were less likely to develop infection (odds ratio 0.21; 95% CI 0.05-0.96). CONCLUSION: Rifaximin-α led to resolution of overt and covert HE, reduced the likelihood of infection, reduced oralisation of the gut and attenuated systemic inflammation. Rifaximin-α plays a role in gut barrier repair, which could be the mechanism by which it ameliorates bacterial translocation and systemic endotoxemia in cirrhosis. CLINICAL TRIAL NUMBER: ClinicalTrials.gov NCT02019784. LAY SUMMARY: In this clinical trial, we examined the underlying mechanism of action of an antibiotic called rifaximin-α which has been shown to be an effective treatment for a complication of chronic liver disease which effects the brain (termed encephalopathy). We show that rifaximin-α suppresses gut bacteria that translocate from the mouth to the intestine and cause the intestinal wall to become leaky by breaking down the protective mucus barrier. This suppression resolves encephalopathy and reduces inflammation in the blood, preventing the development of infection.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Patel VC, Lee S, McPhail MJW, et al. Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial. J Hepatol. 2021. PMID: 34571050. doi:10.1016/j.jhep.2021.09.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。